Neutral sphingomyelinase 1 (NSMase1) mediates caspase-3 activation and apoptosis. However, the role of NSMase1, especially exosome-borne NSMase1 in hepatocellular carcinoma (HCC), remains unclear. We report that NSMase1, which converts sphingomyelin (SM) to ceramide, was significantly downregulated in HCC tissues. Low NSMase1 expression predicted poor long-term survival of HCC patients. NSMase1 downregulation in HCC resulted in increased SM and reduced ceramide (Cer) that led to an increased SM/Cer ratio. Interestingly, NSMase1 and NSMase activity were also decreased in exosomes isolated from HCC tissues and cell lines. Furthermore, NSMase activity increased in exosomes isolated from the culture medium of L02 cells transfected with pEGFP-C3-NSMase1 (NSMase1-Exo). NSMase1-Exo suppressed HCC cell growth and induced apoptosis via reduction of the SM/Cer ratio. Thus, NSMase1 in exosomes inhibits HCC growth by decreasing the SM/Cer ratio.
Introduction
Liver cancer is one of the most common solid malignancies worldwide, and more than 782 000 individuals are expected to be diagnosed with liver cancer annually, causing premature death for more than 745 000 individuals [1] . Hepatocellular carcinoma (HCC), the most common liver malignancy (70-90%), is an aggressive cancer [1, 2] , and at diagnosis, most HCC patients are at advanced or unresectable stages because earlier stages are largely asymptomatic [3] . Data show that hepatotectomy is the best therapeutic strategy for HCC [4, 5] , but long-term survival remains unsatisfactory. Apoptotic resistance is a significant factor in HCC carcinogenesis and progression and a major reason for therapy failure [6, 7] . Therefore, molecular targets that promote apoptosis and suppress HCC growth are urgently needed.
Ceramide (Cer), a neutral lipid of sphingolipid metabolism that is a hydrolytic product of sphingomyelin (SM) via sphingomyelinase, acts as a powerful tumor suppressor lipid due to its role in autophagic responses, cell cycle arrest, and apoptosis promotion by potentiating cell death signaling cascades [8, 9] . Low Cer is associated with tumor progression and poor prognosis in studies of glial tumors and ovarian malignant tumors [10, 11] . Krautbauer's group [12] suggested that Cer was significantly decreased in HCC tissues, and SM was greater compared with adjacent nontumorous tissues (ANLT), indicating that Cer and SM are closely associated with HCC. In addition, enzymes involved in ceramide metabolism, including sphingomyelinase, are implicated in the regulation of cancer cell growth and/or survival [12] [13] [14] . However, whether sphingomyelinase-catalyzed SM conversion to Cer plays an important role in HCC carcinogenesis and progression needs more study.
Neutral sphingomyelinase 1 (NSMase1) functions as an enzyme converting sphingomyelin to ceramide and is activated in response to chemotherapeutic agents, irradiation, and stress. NSMase1 is mainly distributed in the plasma membrane and endoplasmic reticulum [15, 16] . Increasing evidence shows that NSMase1 is associated with many physiological and pathological processes. During T-cell receptor responses, inhibition of NSMase1 decreases ceramide, IL-2 production, and MAPK activation [17] . In zebrafish development, knockdown of NSMase1 generates an abnormal phenotype due to blockage of epiboly formation and neurogenesis. Such phenotypic arrest can be rescued by exogenous Cer, indicating that NSMase1 and its production of Cer are critical for normal development and embryogenesis. Moreover, inactivation of NSMase1 decreases Cer generation and represses the induction of caspase-3 activation and apoptotic cell death by heat stress [18] . Recent data show that phosphorylation of NSMase1 is a pivotal step in JNK signaling, which leads to Cer generation and apoptosis under stress conditions and in response to cytokine stimulation. NSMase1 has a common central role in Cer signaling during stress, cytokine responses and apoptosis [19] . Thus, NSMase1 is closely associated with Cer generation and apoptosis. Also, NSMase2, an NSMase family member, was reported to be a tumor suppressor gene in HCC [20] ; however, whether and how NSMase1 functions as a potential suppressor gene in HCC is unclear. To our knowledge, the roles and the mechanisms underlying NSMase1 in HCC development have not yet been determined. Thus, we report that NSMase1 is downregulated in HCC, and low NSMase1 expression is an independent predictor of survival in HCC patients after liver cancer resection. Moreover, exosomal NSMase1 and NSMase activity are also downregulated in HCC. Exosome-delivered NSMase1 suppresses cell growth and induces apoptosis by lowering the SM/Cer ratio. From these results, we conclude that exosome-delivered NSMase1 inhibits HCC progression via normalization of the SM/Cer ratio.
Results

NSMase1 is significantly downregulated in HCC
NSMase1 expression was measured in HCC tissues as well as corresponding ANLTs using RT-PCR, and NSMase1 mRNA in tumor specimens was significantly lower compared with ANLTs (Fig. 1A) . Then, qRT-PCR data showed that in 142 cases of HCC tissues and ANLTs (Fig. 1B) , NSMase1 was downregulated in tumor tissues. Western blotting confirmed these results (Fig. 1C) . Also, IHC images indicated that NSMase1 decreased in HCC and was primarily expressed in the cytomembrane and cytoplasm (Fig. 1D) . Therefore, expression of NSMase1 was downregulated in HCC tissues compared with ANLTs, suggesting that NSMase1 plays an important role in the development of HCC.
Low NSMase1 expression predicts poor survival of HCC patients
We assessed clinicopathological data and NSMase1 expression based on expression of NSMase1 confirmed with qRT-PCR. 'High' and 'low' groups were determined by 'ANLT/T,' which is the ratio of NSMase1 expression in adjacent noncancerous liver tissues (ANLT) to tumor tissues (T). Patients with ANLT/T ratio greater than two were classified into the 'low' group, while patients with ANLT/T ratio less than two were categorized into the 'high' group. Data showed that NSMase1 expression was associated with tumor size, TNM stage, and tumor recurrence ( Fig. 2 and Table 1 ). There was no statistically significant correlation between NSMase1 expression and other patient factors as described in Table 1 . To clarify a relationship between NSMase1 expression and prognosis of HCC patients, Kaplan-Meier curves were applied to delineate disease-free survival (DFS) and overall survival (OS) curves separately. A log-rank test was used to compare differences between low NSMase1 and high NSMase1 groups. Data showed that low NSMase1 expression was correlated with adverse outcomes for DFS and OS (Fig. 2) . Furthermore, Cox proportional hazard regression analysis to analyze risk factors that affected DFS and OS of HCC patients and univariate and multivariate analysis revealed that low NSMase1 expression was an independent risk factor for DFS and OS for HCC patients after liver resection (Tables 2 and 3 ). Thus, low NSMase1 expression correlates with poor prognosis and may serve as a potential prognosis biomarker for HCC patients.
NSMase1 plays a pivotal role in the SM/Cer imbalance in HCC It's well known that NSMase1 functions as an important enzyme which hydrolyzes sphingomyelin to produce ceramide. NSMase1 frequently is downregulated in HCC, however, about SM and Cer in HCC is little known. SM and Cer in HCC tissues were measured using ESI/MS/ MS analyses on a Thermo Finnigan TSQ 7000 triple quadrupole mass spectrometer (Thermo Scientific, Waltham, MA, USA) operating in a multiple reaction. SM was higher in HCC compared with NLT or ANLT, but there was no difference between NLT and ANLT (Fig. 3A) . Cer in HCC was decreased (Fig. 3B) . The ratio of SM and Cer reflects enzymatic reactions responsible for Cer formation, so we assessed this ratio and it was significantly increased in HCC tissues (Fig. 3C) , indicating that NSMase1 is related to SM/Cer imbalance in HCC. Low NSMase1 expression was positively correlated with a high ratio of SM/Cer in HCC (r = 0.532, P = 0.03), suggesting that NSMase1 is vital to HCC and leads to a high SM/Cer ratio.
NSMase1 may exert its effect via carrier exosomes in HCC
We measured NSMase1 content and NSMase activity in exosomes isolated from HCC tissues, and data showed that NSMase1 protein in exosomes isolated from HCC tissues was significantly decreased compared with ANLTs (Fig. 4A) . Also, NSMase activity in exosomes isolated from HCC tissues was significantly lower than in ANLTs (Fig. 4B) , indicating that NSMase1 probably exerts its effect via exosome as a carrier in HCC. NSMase1 expression and NSMase activity were measured in exosomes from HCC cell culture media and NSMase1 mRNA expression was significantly downregulated in SMMC7721 cells compared with L02 cells (Fig. 4C ). NSMase1 protein (Fig. 4D ) and NSMase activity (Fig. 4E ) in exosomes isolated from culture medium of SMMC7721 cells were significantly lower than in exosomes from medium of L02 cells, suggesting that NSMase1 may exert its function via exosomes as a vehicle.
Exogenous expression of NSMase1 increases NSMase1 protein and NSMase activity in exosomes
Our results showed that NSMase1 mRNA expression (Fig. 5A ) and NSMase activity (Fig. 5B ) in L02 cells transfected with pEGFP-C3-NSMase1 were significantly increased compared with controls. Next, we measured NSMase1 protein and NSMase activity in NSMase1-Exo. Fig. 5C showed that NSMase1 protein increased and NSMase1-Exo had higher NSMase activity compared with Con-Exo. Therefore, stably transfected NSMase1 in L02 cells increases NSMase activity in NSMase1-Exo.
NSMase1-Exo suppresses cell growth and induces apoptosis by lowering the SM/Cer ratio
After SMMC7721 cells were treated with NSMase1-Exo or Con-Exo, SM and Cer were measured and the ratio of SM/Cer was analyzed. Data showed that NSMase1-Exo significantly reduced the ratio of SM/ Cer in SMMC7721 cells (Fig. 5D ). Data to show how NSMase1-Exo affects apoptosis and cell proliferation suggested that NSMase1-Exo significantly induced apoptosis compared with vehicle or Con-Exo (Fig. 5E ). Also, cell growth was inhibited with NSMase1-Exo treatment compared to vehicle or ConExo treatment (Fig. 5F ). Thus, NSMase1-Exo inhibits cell growth and promotes apoptosis by lowering the SM/Cer ratio.
Discussion
Sphingolipids are recognized for their participation in the regulation of cancer cell proliferation and apoptosis and in responses to chemotherapeutic drugs [10, 21] . Cer, a central molecule in sphingolipid metabolism, is key to various aspects of cancer biology including apoptosis, cell cycle arrest, cell proliferation, cell migration, senescence, and inflammation [9, 22, 23] . Defects in Cer production and metabolism in various cancer cells contribute to tumor cell survival, resistance to chemotherapy, and tumor progression. The genes involved in Cer synthesis and catabolism also play important roles in cancer progression, so identifying Cer-related enzymes and lipids in HCC is an important area of research. We previously reported that sphingosine-1-phosphate (S1P), which is a Cer catabolismrelated bioactive phospholipid involved in cancer progression, is significantly higher in HCC tissues than in peri-tumor tissue homogenates [24] . Thus, we focused on Cer-generating-related enzymes.
Sphingomyelinases (SMases) catalyze the hydrolysis of SM to generate Cer. SMases divide into acid SMase (ASMase), neutral SMase (NSMase), and alkaline SMase according to the pH optima of their activities. Of these, ASMase activity deficiency causes Niemann-Pick disease, whereas alkaline SMase is thought to break down dietary SM. NSMase includes NSMase1, NSMase2 and NSMase3. Increasing evidence shows that SMases are involved in cancers, including HCC. For example, Savic's group reported that recombinant human ASMase plus sorafenib had a synergistic effect on reducing tumor volume and blood vessel density in liver cancer [25] . A genome-wide methylation analysis showed that NSMase2 acted as a tumor suppressor gene that could affect tumor aggressiveness. Then, downregulated NSMase2 was reported to be an independent prognostic factor for early recurrence of HCC [20] . Meanwhile, Corcoran's group suggested that NSMase3 was differentially expressed in matched normal tissues and tumor samples, indicating that NSMase3 was deregulated in human malignancies [26] . These studies indicated that SMases were closely related to cancer.
To determine the role of these SMases in HCC, the mRNA expression of SMases was measured with semiquantitative PCR in four pairs of HCC tissue and ANLT, and we found that only NSMase1 expression was downregulated consistently (Fig. 1A , the data of NSMase2 and NSMase3 not shown). Therefore, NSMase1 may have research value for HCC. As a member of the NSMase family, NSMase1 can hydrolyze SM to produce Cer, and NSMase1 is associated with caspase-3 activation and apoptosis [18, 19] . Therefore, we speculate that NSMase1 is the 'switch' that may directly mediate HCC apoptosis.
This study offers the first evidence to verify a role for NSMase1 in HCC. Cer, which is depressed in cancer, acts as a powerful tumor suppressor lipid, so Cer-generated-enzyme activity maybe theoretically weakened in HCC. Supporting our hypothesis, our results validate that NSMase1 mRNA and protein is significantly lower in HCC tissues compared with ANLTs ( Fig. 1) . Furthermore, low NSMase1 was related to big tumor size, TNM stage III-IV, and high recurrence, all of which contribute to poor prognosis for HCC. Evidence confirmed that tumors > 5 cm are unfavorable prognostic factors for HCC patient outcomes [27, 28] . Also, TNM stage III-IV, an advanced stage for HCC classification, is associated with poor prognosis of HCC. As expected, our results demonstrated that HCC patients with low NSMase1 expression had shorter survival times compared with high-NSMase1 patients. Given our findings suggest that NSMase1 (which catalyzes SM to produce Cer) is downregulated in HCC and associated with the prognosis of HCC patients, we hypothesize that SM and Cer may be altered in HCC tissues and ANLTs. Our results demonstrate that SM in HCC is elevated, and Cer is decreased in HCC tissues compared with ANLTs. These data, together with a recent report that showed that HCC tissues are characterized by reduced Cer and increased SM compared with ANLTs and that impaired SMase's activity might be an underlying mechanism of HCC development [12] , indicate that low NSMase1 expression might be involved in HCC progression. Cer is regarded as a tumor suppressor, and Cer is diminished in HCC tissues [29] . However, SM has been reported to be downregulated in serum of HCC patients compared with healthy controls [30] . This result is not consistent with data from HCC tissues and cells. Therefore, we assessed the ratio of SM/ Cer in HCC to better understand the relationship between NSMase1 expression and HCC. Our data suggest that low NSMase1 expression increased the ratio of SM/Cer in HCC tissues compared with ANLTs.
Exosomes, which are vesicles with diameters < 150 nm, function in transporting RNAs, lipids, proteins (or enzymes), drugs and even viruses between cells [31, 32] . Published data show that exosomes play a role in immune escape, drug resistance, and tumor progression [33, 34] . Moreover, our previous data show that exosomes act as carriers to transport enzymes to target cells or organs [35] . In this study, we found that NSMase1 expression and NSMase activity in exosomes isolated from HCC tissues and those isolated from Bold indicates P value less than 0.05, the items with statistical significance.
HCC cell culture medium were significantly decreased. These data remind us that NSMase1 is possibly secreted outside via exosomes and then exerts its role in HCC. Our data also suggest that high exogenous expression of NSMase1 in L02 significantly increased NSMase activity in exosomes isolated from the culture medium of transfected cells, confirming this aforementioned hypothesis. Interestingly, it has been reported that the transfer of exosome-associated domains into the lumen of the endosome required ceramide, and purified exosomes enriched in ceramide, release of exosomes was reduced after inhibition of NSMase [36] . In agreement with these results, a study of prion protein packaging and transmission showed that inhibition of the NSMase pathway using GW4869 impaired exosome biogenesis, and lentivirus-mediated RNAi depletion of NSMase reduced exosome release, demonstrating that the NSMase pathway regulates the biogenesis and release of exosomes [37] . Therefore, we can speculate that upregulation of NSMase promotes exosome formation and release and then produces more ceramide. Supporting our hypothesis, we found that stable transfected NSMase1 in L02 cells increases NSMase activity in NSMase1-Exo; NSMase1-Exo treatment significantly reduces the ratio of SM/Cer; and NSMase1-Exo blocks cell growth and promotes cell apoptosis. However, in this study, we cannot answer how NSMase1-Exo enters the cells and increases ceramide and where it works; these still need more exploration. Exosomes have been proposed not only as diagnostic biomarkers of cancers, but also as vehicles for the delivery of therapeutic agents and anticancer vaccines. Our results showed that exosomal NSMase1 inhibits SMMC7721 cell growth and induces apoptosis by lowering the SM/Cer ratio in vitro, suggesting that exosomal NSMase1 might be a potential candidate of anti-HCC agents. In summary, our findings demonstrate an important role for NSMase1 via exosome secretion in inhibiting liver cancer progression by balancing sphingomyelin and ceramide, uncovering the novel mechanism of HCC apoptosis. Bold indicates P value less than 0.05, the items with statistical significance.
Materials and methods
Reagents
Polyclonal anti-NSMase1 antibody was purchased from Novus (Littleton, CO, USA) and b-actin antibody was obtained from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). Monoclonal anti-CD63 antibody was purchased from BD Pharmingen (San Diego, CA, USA). Centrifuge filter units (molecular weight cut-off of 10 kDa) were from Millipore (Watford, UK). A Cell Death Detection ELISA PLUS Kit was obtained from Roche Applied Science (Indianapolis, IN, USA) and the Micro BCA protein assay kit was purchased from Thermo Scientific (Rockford, IL, USA). An MTT kit was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Patients and tissue specimens
From May 2001 to June 2007, 142 pairs of HCC and adjacent noncancerous liver tissue (ANLT) were selected from patients who underwent routine curative hepatotectomy at the Affiliated Hospital of Guilin Medical University. HCC diagnoses of all patients were confirmed by pathological examination by two independent certified pathologists in the Department of Pathology at Affiliated Hospital of Guilin Medical University. All patients included had no preoperative transhepatic arterial embolization or any other anticancer treatments; had no distant metastasis; had complete resection confirmed by the cut surface being cancer-free; and had complete clinicopathologic and follow-up data. Clinical and pathological features for patients, including age, gender, family history, HBsAg, AFP, tumor size, cirrhosis, tumor number, wine-drinking, TNM stage, PVTT, distant metastasis, and recurrence appear in Table 1 . The sixth edition of the tumor node metastasis (TNM) classification system was used to estimate tumor stagingrespectively. Study procedures and patient data were approved by the hospital ethics committee of Guilin Medical University and complied with the Declaration of Helsinki. Written informed consent was obtained from all patients. Samples were snap-frozen in liquid nitrogen and stored at À80°C for the gene expression assay, and formalin-fixed, paraffin-embedded for the immunohistochemistry assay.
Follow-up and prognostic study
Follow-up data were collected by telephone or visits from the date of surgery to the date of death or the last follow up by a clinical specialist. Patients who underwent hepatotectomy were recommended to supervise liver function, AFP, chest X-ray and liver ultrasonography every 3 months during the first 2 years and twice a year thereafter. For suspected recurrences, high-resolution contrastenhanced CT and/or magnetic resonance imaging (MRI) were performed to confirm lesions. Overall survival (OS) was defined as the interval from the date of surgery to the date of death or last follow-up. Disease-free survival (DFS) was measured from the date of surgery to the date of recurrence or/and metastasis. Clinical follow-up data were held confidential until statistical analyses.
Cell culture
The SMMC7721 human liver cancer cell line and a L02 human normal liver cell line were obtained from Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). They were cultured at 37°C in Dulbecco's modified Eagle's medium (DMEM; HyClone Corp, Logan, UT, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; HyClone Corp), 100 UÁmL À1 penicillin and 100 lgÁmL À1 streptomycin in an atmosphere containing 5% CO 2 . Stable L02 cells transfected with pEGFP-C3-NSMase1 (a gift from Q. Zhu, Nanjing Medical University, Nanjing, China) or control vector pEGFP-C3 (Clontech Laboratories, Inc., Mountain View, CA, USA) were established as previously reported [38] . Briefly, L02 cells were transfected with pEGFP-C3-NSMase1, and then cells were incubated in selection medium containing 400 lgÁmL À1 G418 after 48 h transfection. After 1 month of selection, L02 over-expressed NSMase1 stable clones were isolated.
RNA isolation and cDNA synthesis
Total RNAs were extracted from frozen tumor tissues and hepatocyte cells by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the instructions provided by the manufacturer. RNA was measured using an ultraviolet spectrophotometer and RNA quality was confirmed by visualization of ribosomal RNAs (28S and 18S) on 1.2% agarose gel. According to the manufacturer' protocol, firststrand complementary DNA (cDNA) was synthesized using the Prime Script RT Reagent Kit (TaKaRa, Otsu, Japan). Finally, the first-strand cDNA was kept at À20°C until use.
Semi-quantitative PCR and quantitative real-time PCR
Primers were synthesized by the Beijing Genomics Institute (BGI)-Shenzhen Co., Ltd (Shenzhen, China). Primer sequences used are as follows: Forward primer for NSMase1 was 5 0 -CAGGAGCTTACCCAGCACAT-3 0 ; the reverse primer was 5 0 -GTTGAGCACCATGCCACTTA-3 0 .
The forward primer sequence of b-actin was 5 0 -GACAG GATGCAGAAGGAGATTACT-3 0 , and the reverse primer sequence was 5 0 -TGATCCACATCTGCTGGAAGGT-3 0 .
PCR amplification was performed in a 15 lL reactive system using TaKaRa PCR kits. Reactive programs were predenaturation for 5 min at 94°C, denaturation for 30 s at 94°C, annealing for 30 s at 55°C, extension for 30 s at 72°C, elongation for 5 min at 70°C, and the reaction was terminated at 4°C. PCR was performed for 28 cycles (b-actin) or 32 cycles (NSMase1). PCR products were stained with ethidium bromide and visualized on a 2% agarose gel after resolution via electrophoresis. Quantitative real-time PCR (qRT-PCR) was performed, using 15 lL of reaction system containing 1 lL cDNA (400-1000 ng), and 0.4 lL forward and reverse primers mixed (10 pM), 6.1 lL ddH 2 O and 7.5 lL of FastStart Universal SYBR Green Master Mix (Takara, Shiga, Japan) on a Bio-Rad CFX connect Real-Time System (Bio-Rad, Hercules, CA, USA). Primer sequences for NSMase1 and b-actin are described above. The following PCR cycling protocols were carried out: 95°C for 10 min, then 40 cycles of denaturation at 95°C for 30 s, then 55°C for 30 s, followed by 72°C for 30 s. A melt-curve assay was added to NSMase1-Exo significantly reduced the ratio of SM/Cer. # vs. ###: P < 0.05; ## vs. ###: P < 0.05; # vs. ##: P > 0.05. (E) SMMC7721 cells were treated with NSMase1-Exo, Con-Exo, or vehicle for 24 h, and then apoptosis measured. * vs. ***: P < 0.05, ** vs. ***: P < 0.05; * vs. **: P > 0.05. (F) SMMC7721 cells were treated with NSMase1-Exo, Con-Exo, or PBS for 24 h, and then SMMC7721 cell growth was analyzed with trypan blue or MTT. + vs. +++: P < 0.05, ++ vs. +++: P < 0.05; + vs. ++: P > 0.05. Data obtained from three individual experiments and expressed as fold-change of control (mean AE SD).
measure formation of primer-derived trimers and dimers. NSMase1 expression was normalized to b-actin. The 2 ÀDDCt method was used to calculate gene expression differences between ANLTs and tumor tissues or between L02 and SMMC7721.
Western
Proteins were quantified using a Micro BCA assay kit. Equal amounts of proteins were resolved with 10% SDS/ PAGE and transferred onto PVDF membranes (Amersham, GE Healthcare, NJ, USA). The membrane was blocked with 5% skim milk for 1 h. After that, the membrane was incubated overnight with NSMase1 primary antibody, CD63 antibody or b-actin antibody at 4°C. The next day, the membrane was incubated with secondary antibody for 1 h at 37°C. The antigen-antibody complex on the membrane was visualized by incubating the membrane with ECL (Thermo Scientific, Waltham, MA, USA), and X-ray films.
Immunohistochemistry (IHC)
Tissue slides were provided by the Department of Pathology at Affiliated Hospital of Guilin Medical University. IHC staining for NSMase1 were performed in two-step method using the streptavidin-peroxidase system (Zhongshan Golden Bridge Biotechnology, Beijing). In brief, slides were deparaffinized with xylene and rehydrated in series of graded ethanol. Slides were incubated in 3% H 2 O 2 solution in methanol for 30 min to block endogenous peroxidase activity. Antigen retrieval was performed using citrate buffer at 95-100°C for 2 min. Then slides were incubated with 10% normal goat serum for 30 min to reduce nonspecific reactions at room temperature. Subsequently, slides were incubated in a humidified chamber with rabbit polyclonal anti-NSMase1 antibody (1:200, Cat. No. NBP1-87811; Novus) at 4°C overnight. The next day, tissues were incubated with a biotinylated goat anti-rabbit antibody for 1 h and stained with 3,3 0 -diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich). Slides were counterstained with hematoxylin, and then dehydrated and covered with a coverslip. Finally, stainings were observed and microscopic images were obtained.
Quantification of sphingomyelin and ceramide
Liver tissue homogenates were prepared and cells were collected. Lipids were extracted from homogenates and cells using the Bligh/Dyer method, and sphingomyelin and ceramide were quantified using ESI/MS/MS analyses [39] . Data were normalized to total phospholipid content and expressed as a percent of control.
Exosome isolation, characterization and treatment
Exosomes were isolated from tissues as described in the literature [40] . In brief, HCC tissues and ANLTs were incubated in dissociation buffer and disaggregated gently with tweezers. Samples were kept at 37°C for 1 h. Then, disaggregated samples were centrifuged at 1000 g for 10 min, followed 2000 g for 20 min and 4000 g for 30 min, and then 10 000 g for 1 h (supernatant was collected each time). By centrifuging the samples at 100 000 g for 1.5 h at 4°C, tissue exosomes were pelleted and then ice-cold PBS was used to re-suspend the pellet which was loaded on a sucrose gradient (8, 30, 45 and 60% sucrose in 20 mM TrisCl, 20 mM Hepes, pH 7.2) for exosome purification [41] . The conditioned medium from L02 cells transfected with pEGFP-C3-NSMase1 or control vector pEGFP-C3 was prepared and then used for exosome isolation as described previously [42] . Briefly, cell culture medium was ultracentrifuged at 110 000 g and 4°C for 70 min and pellets were resuspended in PBS for a second ultracentrifugation. Size distribution of exosomes was analysed using a Zetasizer Nano (Malvern Instruments, Malvern, UK). Exosome purity was assessed by western blotting of CD63. The quantitation of exosomes was assessed by ExoELISA-ULTRA Complete Kit (System Biosciences, Palo Alto, CA, USA). Exosome protein was measured using the microbicinchoninic acid assay (microBCA; Thermo Scientific, Rockford, IL, USA), and 10 lg of exosomes was added to hepatocytes seeded in six-well plates.
NSMase activity assay
NSMase activityin cells or exosomes was assayed with using [ 14 C] sphingomyelin according to a previously described protocol [39, 43] .
DNA fragmentation measurement
A cell death detection kit was used to analyze DNA fragments according to the manufacturer's instructions. Briefly, SMMC7721 cells were incubated with lysis buffer, and then cell lysate was centrifuged at 200 g for 10 min. Supernatant was added to immunoreagent mixed with anti-histonebiotin and anti-DNA-peroxidase. After incubation for 2 h at room temperature, substrate for peroxidase was applied and A405 was measured using a spectrophotometer.
Cell growth assay
Trypan blue solution obtained from Thermo Fisher Scientific Inc. and an MTT kit (Sigma, St. Louis, MO, USA) were used to measure viable cells as described in the literature [44, 45] .
